ES2044170T3 - Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen. - Google Patents

Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.

Info

Publication number
ES2044170T3
ES2044170T3 ES89401861T ES89401861T ES2044170T3 ES 2044170 T3 ES2044170 T3 ES 2044170T3 ES 89401861 T ES89401861 T ES 89401861T ES 89401861 T ES89401861 T ES 89401861T ES 2044170 T3 ES2044170 T3 ES 2044170T3
Authority
ES
Spain
Prior art keywords
contain
pharmaceutical compositions
preparation procedure
strontium salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89401861T
Other languages
English (en)
Inventor
Michel Wierzbicki
Jacqueline Bonnet
Yannis Tsouderos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2044170T3 publication Critical patent/ES2044170T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Light Receiving Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA SAL DIESTRONCICA DEL ACIDO (CARBOXIMETIL-1 CARBOXI-2 PIRROLIL-4)-3 PENTANODIOICO, DE FORMULA (I), UTILIZABLE EN TERAPIA, ESPECIALMENTE EN EL TRATAMIENTO DE ENFERMEDADES OSEAS, ENVEJECIMIENTO CUTANEO Y VASCULAR, Y AFECCIONES HEPATICAS.
ES89401861T 1988-06-29 1989-06-29 Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen. Expired - Lifetime ES2044170T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8808729A FR2633619B1 (fr) 1988-06-29 1988-06-29 Nouveau sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant

Publications (1)

Publication Number Publication Date
ES2044170T3 true ES2044170T3 (es) 1994-01-01

Family

ID=9367847

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89401861T Expired - Lifetime ES2044170T3 (es) 1988-06-29 1989-06-29 Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.

Country Status (16)

Country Link
US (1) US4939164A (es)
EP (1) EP0349432B1 (es)
JP (1) JPH0248567A (es)
AT (1) ATE81118T1 (es)
AU (1) AU613297B2 (es)
CA (1) CA1312333C (es)
DE (1) DE68903059T2 (es)
DK (1) DK325289A (es)
ES (1) ES2044170T3 (es)
FR (1) FR2633619B1 (es)
GR (1) GR3006674T3 (es)
IE (1) IE64112B1 (es)
NZ (1) NZ229760A (es)
OA (1) OA09121A (es)
PT (1) PT91006B (es)
ZA (1) ZA894945B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
CA2524610C (en) * 2003-05-07 2014-03-25 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
AU2004237439B2 (en) * 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
AU2005216596B2 (en) * 2004-02-26 2011-03-24 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
ATE443541T1 (de) 2004-06-25 2009-10-15 Strontin Aps Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
US7875627B2 (en) * 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
EP3207188A1 (en) 2014-10-14 2017-08-23 Unilever NV Device for spraying an enclosure triggered by inclination of a rotatable lid
EP3206803A1 (en) 2014-10-14 2017-08-23 Unilever NV Spraying device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2954384A (en) * 1960-09-27 Method for preparing kainic acid and its
DE3127275A1 (de) * 1980-12-11 1983-01-27 Leskovar, Peter, Dr.-Ing., 8000 München "harnsteinaufloesende mittel"

Also Published As

Publication number Publication date
CA1312333C (fr) 1993-01-05
PT91006B (pt) 1994-11-30
OA09121A (fr) 1991-10-31
FR2633619B1 (fr) 1991-02-08
EP0349432A1 (fr) 1990-01-03
ATE81118T1 (de) 1992-10-15
IE892094L (en) 1989-12-29
GR3006674T3 (es) 1993-06-30
FR2633619A1 (fr) 1990-01-05
ZA894945B (en) 1990-03-28
NZ229760A (en) 1991-06-25
JPH0248567A (ja) 1990-02-19
DE68903059D1 (de) 1992-11-05
JPH0587064B2 (es) 1993-12-15
DK325289D0 (da) 1989-06-29
AU3709289A (en) 1990-01-04
DK325289A (da) 1989-12-30
PT91006A (pt) 1989-12-29
US4939164A (en) 1990-07-03
EP0349432B1 (fr) 1992-09-30
DE68903059T2 (de) 1993-04-29
IE64112B1 (en) 1995-07-12
AU613297B2 (en) 1991-07-25

Similar Documents

Publication Publication Date Title
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
NL300168I2 (nl) Tweewaardige metaalzouten van 2-N,N-di(cararboxymethyl)amino-3-cyaan-4-carboxymethyl-5-thiofeencarbonzuur, werkwijze voor de bereiding ervan en deze bevattende farmaceutische preparaten.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
IT8319306A0 (it) Composizione di antralina oppure di uno dei suoi derivati in un estere aromatico e suo impiego nel trattamento di malattie della pelle e delle unghie.
SE7902742L (sv) Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
DE3866045D1 (de) Arzneimittel zur behandlung von uraemie.
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
ES2054089T3 (es) Formulaciones orales liquidas.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
ZA814902B (en) Novel thiazol-2-yl-oxamic acid derivatives,their preparation and therapeutic agents containing these compounds
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ES2063765T3 (es) Esteres cicloalifaticos insaturados de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 349432

Country of ref document: ES